Global Physician Survey on Stents, Stent-Grafts and Vulnerable Plaque Treatment 2011

Date: January 22, 2011
Pages: 307
Price:
US$ 11,495.00
License [?]:
Publisher: iData Research Inc.
Report type: Strategic Report
Delivery: E-mail Delivery (PDF), Hard Copy Mail Delivery
ID: G923BD166EEEN
Leaflet:

Download PDF Leaflet

Global Physician Survey on Stents, Stent-Grafts and Vulnerable Plaque Treatment 2011
This report details the responses of a comprehensive survey conducted of interventional cardiologists, interventional radiologists and cardiac surgeons on product preferences, placement techniques and trends in the use of drug eluting and bare metal stents, bifurcated stents, bioabsorbable stents, stent grafts, vulnerable plaque diagnosis and treatment and endovascular imaging technologies. The Global Physician Survey on Stents, Stent-Grafts and Endovascular Imaging includes:
  • The United States
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East
  • Africa
This report covers:
  • Number and Type of Stents Placed
  • Type of Endovascular Imaging Used
  • Bifurcated Stents and Their Use
  • Most Important Benefit When Using Bifurcated Stents
  • Preferred Bifurcated Stent Alternative
  • Bioabsorbable Stents and Their Use
  • Most Important Benefit When Using Bioabsorbable Stents
  • Most Important Bioabsorable Stent Drawback
  • Most Important Drug-Eluting Stent Concern
  • Most Effective Drug-Eluting Stent Drug for Combating Restenosis
  • Stent-Graft Brand Preference
  • Most Important Construction Feature for Stent-Grafts
  • Most Important Design Feature for Next Generation Stent-Grafts
  • The Use of Thoracic Aortic Aneurysm (TAA) Stent-Grafts
  • Concerns about the Use of TAA Stent-Grafts
TABLE OF CONTENTS

LIST OF FIGURES
LIST OF CHARTS

1. EXECUTIVE SUMMARY

1.1 SURVEY OVERVIEW
1.2 CORONARY AND PERIPHERAL STENTS
1.3 ENDOVASCULAR IMAGING TECHNOLOGY
1.4 BIFURCATED STENT BENEFITS AND DRAWBACKS
1.5 ALTERNATIVES TO BIFURCATED STENTS
1.6 BIOABSORBABLE STENT BENEFITS AND DRAWBACKS
1.7 DRUG-ELUTING STENTS
1.8 IMPORTANT STENT-GRAFT CONSTRUCTION FEATURES
1.9 STENT-GRAFT BRAND PREFERENCE
1.10 THORACIC ABDOMINAL ANEURYSM STENT-GRAFTS
1.11 VULNERABLE PLAQUE SCREENING
1.12 VULNERABLE PLAQUE TREATMENT
1.13 LIST OF COUNTRIES AND TOPICS

2. SURVEY HIGHLIGHTS

2.1 RESPONDENT CHARACTERISTICS
2.2 RESPONSE SUMMARY

3. RESEARCH METHODOLOGY

3.1 RESEARCH SCOPE

4. GLOBAL STENTS, STENT-GRAFTS AND VULNERABLE PLAQUE

4.1 INTRODUCTION
  4.1.1 Bioabsorbable Stents
  4.1.2 Bifurcated Stents
  4.1.3 Stent-Grafts
  4.1.4 Vulnerable Plaque
4.2 GLOBAL OVERVIEW FOR STENTS, STENT-GRAFTS AND VULNERABLE PLAQUE
  4.2.1 Geographical Distribution
  4.2.2 Respondent Specialty
  4.2.3 Number and Type of Stents Placed
  4.2.4 Type of Endovascular Imaging Used
  4.2.5 Bifurcated Stents and Their Use
  4.2.6 Most Important Benefit of Bifurcated Stents
  4.2.7 Most Important Bifurcated Stent Drawback
  4.2.8 Preferred Bifurcated Stent Alternatives
  4.2.9 Bioabsorbable Stents and Their Use
  4.2.10 Most Important Bioabsorbable Stent Benefit
  4.2.11 Most Important Bioabsorbable Stent Drawback
  4.2.12 Most Important Drug-Eluting Stent Concern
  4.2.13 Most Effective Drug-Eluting Stent Drug for Combating Restenosis
  4.2.14 Stent-Graft Brand Preference
  4.2.15 Most Important Construction Feature for Stent-Grafts
  4.2.16 Most Important Design Feature for Next-Generation Stent-Grafts
  4.2.17 The Use of Thoracic Aortic Aneurysm (TAA) Stent-Grafts
  4.2.18 Concerns about the Use of TAA Stent-Grafts
  4.2.19 Most Promising Vulnerable Plaque Screening Technology
  4.2.20 Most Promising Vulnerable Plaque Treatment Technology

5. U.S. STENTS, STENT-GRAFTS AND VULNERABLE PLAQUE

5.1 GEOGRAPHICAL DISTRIBUTION
5.2 RESPONDENT SPECIALTY
5.3 NUMBER AND TYPE OF STENTS PLACED
5.4 TYPE OF ENDOVASCULAR IMAGING USED
5.5 BIFURCATED STENTS AND THEIR USE
5.6 MOST IMPORTANT BENEFIT WHEN USING BIFURCATED STENTS
5.7 DRAWBACKS TO THE USE OF BIFURCATED STENTS
5.8 PREFERRED BIFURCATED STENT ALTERNATIVES
  5.8.1 Preferred Bifurcated Stent Alternatives by Specialty
5.9 BIOABSORBABLE STENTS AND THEIR USE
5.10 MOST IMPORTANT BENEFIT WHEN USING BIOABSORBABLE STENTS
5.11 MOST IMPORTANT BIOABSORBABLE STENT DRAWBACK
5.12 MOST IMPORTANT DRUG-ELUTING STENT CONCERN
5.13 MOST EFFECTIVE DRUG-ELUTING STENT DRUG FOR COMBATING RESTENOSIS
  5.13.1 Most Effective Drug-Eluting Stent Drug for Combating Restenosis by Specialty
5.14 PREFERRED BRAND OF STENT-GRAFT
5.15 MOST IMPORTANT CONSTRUCTION FEATURE FOR STENT-GRAFTS
5.16 MOST IMPORTANT DESIGN FEATURE FOR NEXT-GENERATION STENT-GRAFTS
5.17 THE USE OF THORACIC AORTIC ANEURYSM STENT-GRAFTS
5.18 CONCERNS ABOUT THE USE OF TAA STENT-GRAFTS
5.19 MOST PROMISING VULNERABLE PLAQUE SCREENING TECHNOLOGY
  5.19.1 Most Promising Vulnerable Plaque Screening Technology by Specialty
5.20 MOST PROMISING VULNERABLE PLAQUE TREATMENT TECHNOLOGY
  5.20.1 Most Promising Vulnerable Plaque Treatment Technology by Specialty

6. EUROPEAN STENTS, STENT-GRAFTS AND VULNERABLE PLAQUE

6.1 GEOGRAPHICAL DISTRIBUTION
6.2 RESPONDENT SPECIALTY
6.3 NUMBER AND TYPE OF STENTS PLACED
6.4 TYPE OF ENDOVASCULAR IMAGING USED
6.5 BIFURCATED STENTS AND THEIR USE
6.6 MOST IMPORTANT BENEFIT WHEN USING BIFURCATED STENTS
6.7 DRAWBACKS TO THE USE OF BIFURCATED STENTS
6.8 PREFERRED BIFURCATED STENT ALTERNATIVES
  6.8.1 Preferred Bifurcated Stent Alternatives by Specialty
6.9 BIOABSORBABLE STENTS AND THEIR USE
6.10 MOST IMPORTANT BENEFIT WHEN USING BIOABSORBABLE STENTS
6.11 MOST IMPORTANT BIOABSORBABLE STENT DRAWBACK
6.12 MOST IMPORTANT DRUG-ELUTING STENT CONCERN
6.13 MOST EFFECTIVE DRUG-ELUTING STENT DRUG FOR COMBATING RESTENOSIS
  6.13.1 Most Effective Drug-Eluting Stent Drug for Combating Restenosis by Specialty
6.14 PREFERRED BRAND OF STENT-GRAFT
6.15 MOST IMPORTANT CONSTRUCTION FEATURE FOR STENT-GRAFTS
6.16 MOST IMPORTANT DESIGN FEATURE FOR NEXT-GENERATION STENT-GRAFTS
6.17 THE USE OF THORACIC AORTIC ANEURYSM (TAA) STENT-GRAFTS
6.18 CONCERNS ABOUT THE USE OF TAA STENT-GRAFTS
6.19 MOST PROMISING VULNERABLE PLAQUE SCREENING TECHNOLOGY
  6.19.1 Most Promising Vulnerable Plaque Screening Technology by Specialty
6.20 MOST PROMISING VULNERABLE PLAQUE TREATMENT TECHNOLOGY

7. LATIN AMERICAN STENTS, STENT-GRAFTS AND VULNERABLE PLAQUE

7.1 GEOGRAPHICAL DISTRIBUTION
7.2 RESPONDENT SPECIALTY
7.3 NUMBER AND TYPE OF STENTS PLACED
7.4 TYPE OF ENDOVASCULAR IMAGING USED
  7.4.1 Imaging Technology Preference by Country
7.5 BIFURCATED STENTS AND THEIR USE
7.6 MOST IMPORTANT BENEFIT WHEN USING BIFURCATED STENTS
7.7 DRAWBACKS TO THE USE OF BIFURCATED STENTS
7.8 PREFERRED BIFURCATED STENT ALTERNATIVES
7.9 BIOABSORBABLE STENTS AND THEIR USE
7.10 MOST IMPORTANT BENEFIT WHEN USING BIOABSORBABLE STENTS
7.11 MOST IMPORTANT BIOABSORBABLE STENT DRAWBACK
7.12 MOST IMPORTANT DRUG-ELUTING STENT CONCERN
7.13 MOST EFFECTIVE DRUG-ELUTING STENT DRUG FOR COMBATING RESTENOSIS
7.14 PREFERRED BRAND OF STENT-GRAFT
7.15 MOST IMPORTANT CONSTRUCTION FEATURE FOR STENT-GRAFTS
7.16 MOST IMPORTANT DESIGN FEATURE FOR NEXT-GENERATION STENT-GRAFTS
7.17 THE USE OF THORACIC AORTIC ANEURYSM (TAA) STENT-GRAFTS
7.18 CONCERNS ABOUT THE USE OF TAA STENT-GRAFTS
7.19 MOST PROMISING VULNERABLE PLAQUE SCREENING TECHNOLOGY
7.20 MOST PROMISING VULNERABLE PLAQUE TREATMENT TECHNOLOGY

8. ASIA-PACIFIC STENTS, STENT-GRAFTS AND VULNERABLE PLAQUE

8.1 GEOGRAPHICAL DISTRIBUTION
8.2 RESPONDENT SPECIALTY
8.3 NUMBER AND TYPE OF STENTS PLACED
8.4 TYPE OF ENDOVASCULAR IMAGING USED
  8.4.1 Imaging Technology Preference by Country
8.5 BIFURCATED STENTS AND THEIR USE
8.6 MOST IMPORTANT BENEFIT WHEN USING BIFURCATED STENTS
8.7 DRAWBACKS TO THE USE OF BIFURCATED STENTS
8.8 PREFERRED BIFURCATED STENT ALTERNATIVES
8.9 BIOABSORBABLE STENTS AND THEIR USE
8.10 MOST IMPORTANT BENEFIT WHEN USING BIOABSORBABLE STENTS
8.11 MOST IMPORTANT BIOABSORBABLE STENT DRAWBACK
8.12 MOST IMPORTANT DRUG-ELUTING STENT CONCERN
8.13 MOST EFFECTIVE DRUG-ELUTING STENT DRUG FOR COMBATING RESTENOSIS
8.14 PREFERRED BRAND OF STENT-GRAFT
8.15 MOST IMPORTANT CONSTRUCTION FEATURE FOR STENT-GRAFTS
8.16 MOST IMPORTANT DESIGN FEATURE FOR NEXT-GENERATION STENT-GRAFTS
8.17 THE USE OF THORACIC AORTIC ANEURYSM (TAA) STENT-GRAFTS
8.18 CONCERNS ABOUT THE USE OF TAA STENT-GRAFTS
8.19 MOST PROMISING VULNERABLE PLAQUE SCREENING TECHNOLOGY
8.20 MOST PROMISING VULNERABLE PLAQUE TREATMENT TECHNOLOGY

9. MIDDLE EASTERN AND AFRICAN STENTS, STENT-GRAFTS AND VULNERABLE PLAQUE

9.1 GEOGRAPHICAL DISTRIBUTION
9.2 RESPONDENT SPECIALTY
9.3 NUMBER AND TYPE OF STENTS PLACED
9.4 TYPE OF ENDOVASCULAR IMAGING USED
  9.4.1 Imaging Technology Preference by Country
9.5 BIFURCATED STENTS AND THEIR USE
9.6 MOST IMPORTANT BENEFIT WHEN USING BIFURCATED STENTS
9.7 DRAWBACKS TO THE USE OF BIFURCATED STENTS
9.8 PREFERRED BIFURCATED STENT ALTERNATIVES
9.9 BIOABSORBABLE STENTS AND THEIR USE
9.10 MOST IMPORTANT BENEFIT WHEN USING BIOABSORBABLE STENTS
9.11 MOST IMPORTANT BIOABSORBABLE STENT DRAWBACK
9.12 MOST IMPORTANT DRUG-ELUTING STENT CONCERN
9.13 MOST EFFECTIVE DRUG-ELUTING STENT DRUG FOR COMBATING RESTENOSIS
9.14 PREFERRED BRAND OF STENT-GRAFT
9.15 MOST IMPORTANT CONSTRUCTION FEATURE FOR STENT-GRAFTS
9.16 MOST IMPORTANT DESIGN FEATURE FOR NEXT-GENERATION STENT-GRAFTS
9.17 THE USE OF THORACIC AORTIC ANEURYSM (TAA) STENT-GRAFTS
9.18 CONCERNS ABOUT THE USE OF TAA STENT-GRAFTS
9.19 MOST PROMISING VULNERABLE PLAQUE SCREENING TECHNOLOGY
9.20 MOST PROMISING VULNERABLE PLAQUE TREATMENT TECHNOLOGY

10. ABBREVIATIONS

11. APPENDIX

11.1 GEOGRAPHIC DISTRIBUTION OF RESPONSES
11.2 TECHNIQUES FOR STENTING BIFURCATED LESIONS
11.3 SAMPLE SURVEY

LIST OF FIGURES

EXECUTIVE SUMMARY
SURVEY HIGHLIGHTS
Figure 2-1: Respondent Characteristics, Stents, Stent-Grafts and Vulnerable Plaque, 2010
Figure 2-2: Respondent Characteristics, Stents, Stent-Grafts and Vulnerable Plaque, 2010
RESEARCH METHODOLOGY
GLOBAL STENTS, STENT-GRAFTS AND VULNERABLE PLAQUE
Figure 4-1: Geographical Distribution, Global Respondents, 2010
Figure 4-2: Respondent Specialty, Global Responses, 2010
Figure 4-3: Coronary and Peripheral Stents Placed per Month, Global Responses, 2010
Figure 4-4: Imaging Technology Preferences, Percentage of Use for Respondents, Global Responses, 2010
Figure 4-5: Imaging Technology Preferences for Endovascular Procedures, Global Responses, 2010
Figure 4-6: Bifurcated Stents and Their Use, Global Responses, 2010
Figure 4-7: Most Important Bifurcated Stent Benefit, Global Responses, 2010
Figure 4-8: Most Important Bifurcated Stent Drawback, Global Responses, 2010
Figure 4-9: Preferred Bifurcated Stent Alternatives, Global Responses, 2010 (Part 1 of 2)
Figure 4-10: Preferred Bifurcated Stent Alternatives, Global Responses, 2010 (Part 2 of 2)
Figure 4-11: Bioabsorbable Stents and Their Use, Global Responses, 2010
Figure 4-12: Most Important Bioabsorbable Stent Benefit, Global Responses, 2010 (Part 1 of 2)
Figure 4-13: Most Important Bioabsorbable Stent Benefit, Global Responses, 2010 (Part 2 of 2)
Figure 4-14: Most Important Bioabsorbable Stent Drawback, Global Responses, 2010
Figure 4-15: Most Important Drug-Eluting Stent Concern, Global Responses, 2010
Figure 4-16: Most Effective Drug-Eluting Stent Drug for Combating Restenosis, Global Responses, 2010
Figure 4-17: Stent-Graft Brand Preference, Global Responses, 2010 (Part 1 of 2)
Figure 4-18: Stent-Graft Brand Preference, Global Responses, 2010 (Part 2 of 2)
Figure 4-19: Most Important Construction Feature for Stent-Grafts, Global Responses, 2010 (Part 1 of 2)
Figure 4-20: Most Important Construction Feature for Stent-Grafts, Global Responses, 2010 (Part 2 of 2)
Figure 4-21: Most Important Design Feature for Next-Generation Stent-Grafts, Global Responses, 2010
Figure 4-22: The Use of Thoracic Aortic Aneurysm (TAA) Stent-Grafts, Global Responses, 2010
Figure 4-23: Concerns about the Use of TAA Stent-Grafts, Global Responses, 2010 (Part 1 of 2)
Figure 4-24: Concerns about the Use of TAA Stent-Grafts, Global Responses, 2010 (Part 2 of 2)
Figure 4-25: Most Promising Vulnerable Plaque Screening Technology, Global Responses, 2010 (Part 1 of 2)
Figure 4-26: Most Promising Vulnerable Plaque Screening Technology, Global Responses, 2010 (Part 2 of 2)
Figure 4-27: Most Promising Vulnerable Plaque Treatment Technology, Global Responses, 2010
U.S. STENTS, STENT-GRAFTS AND VULNERABLE PLAQUE
Figure 5-1: Distribution of Survey Respondents by Geographic Region, U.S. Responses, 2010
Figure 5-2: Distribution of Survey Respondents by Specialty, U.S. Responses, 2010
Figure 5-3: Number and Type of Stents Placed, U.S. Responses, 2010
Figure 5-4: Type of Medical Imaging Used for Endovascular Procedures, U.S. Responses, 2010
Figure 5-5: Type of Medical Imaging Used for Endovascular Procedures by Specialty, U.S. Responses, 2010
Figure 5-6: Bifurcated Stents and Their Use, U.S. Responses, 2010
Figure 5-7: Most Important Benefit When Using Bifurcated Stents, U.S. Responses, 2010
Figure 5-8: Drawbacks to the Use of Bifurcated Stents, U.S. Responses, 2010
Figure 5-9: Preferred Bifurcated Stent Alternatives, U.S. Responses, 2010
Figure 5-10: Preferred Bifurcated Stent Alternatives by Specialty, U.S. Responses, 2010
Figure 5-11: Bioabsorbable Stents and Their Use, U.S. Responses, 2010
Figure 5-12: Most Important Benefit When Using Bioabsorbable Stents, U.S. Responses, 2010
Figure 5-13: Most Important Bioabsorbable Stent Drawback, U.S. Responses, 2010
Figure 5-14: Most Important Drug-Eluting Stent Concern, U.S. Responses, 2010
Figure 5-15: Most Effective Drug-Eluting Stent Drug for Combating Restenosis, U.S. Responses, 2010
Figure 5-16: Most Effective Drug-Eluting Stent Drug for Combating Restenosis by Specialty, U.S. Responses, 2010
Figure 5-17: Preferred Brand of Stent-Graft, U.S. Responses, 2010
Figure 5-18: Most Important Construction Feature for Stent-Grafts, U.S. Responses, 2010
Figure 5-19: Most Important Design Feature for Next-Generation Stent-Grafts, U.S. Responses, 2010
Figure 5-20: Use of Thoracic Aortic Aneurysm (TAA) Stent-Grafts, U.S. Responses, 2010
Figure 5-21: Concerns about the Use of TAA Stent-Grafts, U.S. Responses, 2010
Figure 5-22: Most Promising Vulnerable Plaque Screening Technology, U.S. Responses, 2010
Figure 5-23: Most Promising Vulnerable Plaque Screening Technology by Specialty, U.S. Responses, 2010 (Part 1 of 2)
Figure 5-24: Most Promising Vulnerable Plaque Screening Technology by Specialty, U.S. Responses, 2010 (Part 2 of 2)
Figure 5-25: Most Promising Vulnerable Plaque Treatment Technology, U.S. Responses, 2010
Figure 5-26: Most Promising Vulnerable Plaque Treatment Technology by Specialty, U.S. Responses, 2010
EUROPEAN STENTS, STENT-GRAFTS AND VULNERABLE PLAQUE
Figure 6-1: Distribution of Survey Respondents by Geographic Region, European Responses, 2010
Figure 6-2: Distribution of Survey Respondents by Specialty, European Responses, 2010
Figure 6-3: Number and Type of Stents Placed Per Month, European Responses, 2010
Figure 6-4: Type of Medical Imaging Used for Endovascular Procedures, European Responses, 2010
Figure 6-5: Type of Medical Imaging Used for Endovascular Procedures by Specialty, European Responses, 2010
Figure 6-6: Bifurcated Stents and Their Use, European Responses, 2010
Figure 6-7: Most Important Benefit When Using Bifurcated Stents, European Responses, 2010
Figure 6-8: Drawbacks to the Use of Bifurcated Stents, European Responses, 2010
Figure 6-9: Preferred Bifurcated Stent Alternatives, European Responses, 2010
Figure 6-10: Preferred Bifurcated Stent Alternatives by Specialty, European Responses, 2010
Figure 6-11: Bioabsorbable Stents and Their Use, European Responses, 2010
Figure 6-12: Most Important Benefit When Using Bioabsorbable Stents, European Responses, 2010
Figure 6-13: Most Important Bioabsorbable Stent Drawback, European Responses, 2010
Figure 6-14: Most Important Drug-Eluting Stent Concern, European Responses, 2010
Figure 6-15: Most Effective Drug-Eluting Stent Drug for Combating Restenosis, European Responses, 2010
Figure 6-16: Most Effective Drug-Eluting Stent Drug for Combating Restenosis by Specialty, European Responses, 2010
Figure 6-17: Preferred Brand of Stent-Graft, European Responses, 2010
Figure 6-18: Most Important Construction Feature for Stent-Grafts, European Responses, 2010
Figure 6-19: Most Important Design Feature for Next-Generation Stent-Grafts, European Responses, 2010
Figure 6-20: Use of Thoracic Aortic Aneurysm (TAA) Stent-Grafts, European Responses, 2010
Figure 6-21: Concerns about the Use of TAA Stent-Grafts, European Responses, 2010
Figure 6-22: Most Promising Vulnerable Plaque Screening Technology, European Responses, 2010
Figure 6-23: Most Promising Vulnerable Plaque Screening Technology by Specialty, European Responses, 2010
Figure 6-24: Most Promising Vulnerable Plaque Treatment Technology, European Responses, 2010
LATIN AMERICAN STENTS, STENT-GRAFTS AND VULNERABLE PLAQUE
Figure 7-1: Distribution of Survey Respondents by Geographic Region, Latin American Responses, 2010
Figure 7-2: Number and Type of Stents Placed per Month, Latin American Responses, 2010
Figure 7-3: Type of Medical Imaging Used for Endovascular Procedures, Latin American Responses, 2010
Figure 7-4: Type of Medical Imaging Used for Endovascular Procedures by Country, Latin American Responses, 2010
Figure 7-5: Bifurcated Stents and Their Use, Latin American Responses, 2010
Figure 7-6: Most Important Benefit When Using Bifurcated Stents, Latin American Responses, 2010
Figure 7-7: Drawbacks to the Use of Bifurcated Stents, Latin American Responses, 2010
Figure 7-8: Preferred Bifurcated Stent Alternatives, Latin American Responses, 2010
Figure 7-9: Bioabsorbable Stents and Their Use, Latin American Responses, 2010
Figure 7-10: Most Important Benefit When Using Bioabsorbable Stents, Latin American Responses, 2010
Figure 7-11: Most Important Bioabsorbable Stent Drawback, Latin American Responses, 2010
Figure 7-12: Most Important Drug-Eluting Stent Concern, Latin American Responses, 2010
Figure 7-13: Most Effective Drug-Eluting Stent Drug for Combating Restenosis, Latin American Responses, 2010
Figure 7-14: Preferred Brand of Stent-Graft, Latin American Responses, 2010 .
Figure 7-15: Most Important Construction Feature for Stent-Grafts, Latin American Responses, 2010
Figure 7-16: Most Important Design Feature for Next-Generation Stent-Grafts, Latin American Responses, 2010
Figure 7-17: Use of Thoracic Aortic Aneurysm (TAA) Stent-Grafts, Latin American Responses, 2010
Figure 7-18: Concerns about the Use of TAA Stent-Grafts, Latin American Responses, 2010
Figure 7-19: Most Promising Vulnerable Plaque Screening Technology, Latin American Responses, 2010
Figure 7-20: Most Promising Vulnerable Plaque Treatment Technology, Latin American Responses, 2010
ASIA-PACIFIC STENTS, STENT-GRAFTS AND VULNERABLE PLAQUE
Figure 8-1: Distribution of Survey Respondents by Geographic Region, Asia-Pacific Responses, 2010
Figure 8-2: Preferred Imaging Technology for DVT Diagnosis, Asia-Pacific Responses, 2010
Figure 8-3: Number and Type of Stents Placed per Month, Asia-Pacific Responses, 2010
Figure 8-4: Type of Medical Imaging Used for Endovascular Procedures, Asia-Pacific Responses, 2010
Figure 8-5: Type of Medical Imaging Used for Endovascular Procedures by Country, Asia-Pacific Responses, 2010
Figure 8-6: Bifurcated Stents and Their Use, Asia-Pacific Responses, 2010
Figure 8-7: Most Important Benefit When Using Bifurcated Stents, Asia-Pacific Responses, 2010
Figure 8-8: Drawbacks to the Use of Bifurcated Stents, Asia-Pacific Responses, 2010
Figure 8-9: Preferred Bifurcated Stent Alternatives, Asia-Pacific Responses, 2010
Figure 8-10: Bioabsorbable Stents and Their Use, Asia-Pacific Responses, 2010
Figure 8-11: Most Important Benefit When Using Bioabsorbable Stents, Asia-Pacific Responses, 2010
Figure 8-12: Most Important Bioabsorbable Stent Drawback, Asia-Pacific Responses, 2010
Figure 8-13: Most Important Drug-Eluting Stent Concern, Asia-Pacific Responses, 2010
Figure 8-14: Most Effective Drug-Eluting Stent Drug for Combating Restenosis, Asia-Pacific Responses, 2010
Figure 8-15: Preferred Brand of Stent-Graft, Asia-Pacific Responses, 2010
Figure 8-16: Most Important Construction Feature for Stent-Grafts, Asia-Pacific Responses, 2010
Figure 8-17: Most Important Design Feature for Next-Generation Stent-Grafts, Asia-Pacific Responses, 2010
Figure 8-18: Use of Thoracic Aortic Aneurysm (TAA) Stent-Grafts, Asia-Pacific Responses, 2010
Figure 8-19: Concerns about the Use of TAA Stent-Grafts, Asia-Pacific Responses, 2010
Figure 8-20: Most Promising Vulnerable Plaque Screening Technology, Asia-Pacific Responses, 2010
Figure 8-21: Most Promising Vulnerable Plaque Treatment Technology, Asia-Pacific Responses, 2010
MIDDLE EASTERN AND AFRICAN STENTS, STENT-GRAFTS AND VULNERABLE PLAQUE
Figure 9-1: Distribution of Survey Respondents by Geographic Region, Middle Eastern and African Responses, 2010
Figure 9-2: Number and Type of Stents Placed per Month, Middle Eastern and African Responses, 2010
Figure 9-3: Type of Medical Imaging Used for Endovascular Procedures, Middle Eastern and African Responses, 2010
Figure 9-4: Type of Medical Imaging Used for Endovascular Procedures by Country, Middle Eastern and African Responses, 2010
Figure 9-5: Bifurcated Stents and Their Use, Middle Eastern and African Responses, 2010
Figure 9-6: Most Important Benefit When Using Bifurcated Stents, Middle Eastern and African Responses, 2010
Figure 9-7: Drawbacks to the Use of Bifurcated Stents, Middle Eastern and African Responses, 2010
Figure 9-8: Preferred Bifurcated Stent Alternatives, Middle Eastern and African Responses, 2010
Figure 9-9: Bioabsorbable Stents and Their Use, Middle Eastern and African Responses, 2010
Figure 9-10: Most Important Benefit When Using Bioabsorbable Stents, Middle Eastern and African Responses, 2010
Figure 9-11: Most Important Bioabsorbable Stent Drawback, Middle Eastern and African Responses, 2010
Figure 9-12: Most Important Drug-Eluting Stent Concern, Middle Eastern and African Responses, 2010
Figure 9-13: Most Effective Drug-Eluting Stent Drug for Combating Restenosis, Middle Eastern and African Responses, 2010
Figure 9-14: Preferred Brand of Stent-Graft, Middle Eastern and African Responses, 2010
Figure 9-15: Most Important Construction Feature for Stent-Grafts, Middle Eastern and African Responses, 2010
Figure 9-16: Most Important Design Feature for Next-Generation Stent-Grafts, Middle Eastern and African Responses, 2010
Figure 9-17: Use of Thoracic Aortic Aneurysm (TAA) Stent-Grafts, Middle Eastern and African Responses, 2010
Figure 9-18: Concerns about the Use of TAA Stent-Grafts, Middle Eastern and African Responses, 2010
Figure 9-19: Most Promising Vulnerable Plaque Screening Technology, Middle Eastern and African Responses, 2010
Figure 9-20: Most Promising Vulnerable Plaque Treatment Technology, Middle Eastern and African Responses, 2010
ABBREVIATIONS
APPENDIX
Figure 11-1: Geographic Distribution of Responses, U.S., 2010
Figure 11-2: Geographic Distribution of Responses, European Region, 2010
Figure 11-3: Geographic Distribution of Responses, Latin American Region, 2010
Figure 11-4: Geographic Distribution of Responses, Asia-Pacific Region, 2010
Figure 11-5: Geographic Distribution of Responses, Middle Eastern and African Region, 2010

LIST OF CHARTS

EXECUTIVE SUMMARY
Chart 1-1: Respondent Location by Geographic Region, Global Responses, Stents, Stent-Grafts and Vulnerable Plaque, 2010
Chart 1-2: Average Number of Stents Placed per Month by Respondents, Global Responses, Stents, Stent-Grafts and Vulnerable Plaque, 2010
Chart 1-3: Bifurcated Stent Alternatives, Global Responses, Stents, Stent-Grafts and Vulnerable Plaque, 2010
Chart 1-4: Vulnerable Plaque Screening Technology, Global Responses, Stents, Stent-Grafts and Vulnerable Plaque, 2010
Chart 1-5: Most Promising Vulnerable Plaque Treatment, U.S. Respondents, Stents, Stent-Grafts and Vulnerable Plaque, 2010
SURVEY HIGHLIGHTS
RESEARCH METHODOLOGY
GLOBAL STENTS, STENT-GRAFTS AND VULNERABLE PLAQUE
Chart 4-1: Respondent Specialty, Global Responses, 2010
Chart 4-2: Average Stents Placed per Respondent, Global Responses, 2010
Chart 4-3: Imaging Technology Preferences, Percentage of Total, Global Responses, 2010
Chart 4-4: Bifurcated Stents and Their Use, U.S. Responses, 2010
Chart 4-5: Bifurcated Stents and Their Use, European Responses, 2010
Chart 4-6: Bifurcated Stents and Their Use, Latin American Responses, 2010
Chart 4-7: Bifurcated Stents and Their Use, Asia-Pacific Responses, 2010
Chart 4-8: Bifurcated Stents and Their Use, Middle Eastern and African Responses, 2010
Chart 4-9: Most Important Bifurcated Stent Benefit, Global Responses, 2010
Chart 4-10: Most Important Bifurcated Stent Drawback, Global Responses, 2010
Chart 4-11: Preferred Bifurcated Stent Alternatives, U.S. Responses, 2010
Chart 4-12: Preferred Bifurcated Stent Alternatives, European Responses, 2010 .
Chart 4-13: Preferred Bifurcated Stent Alternatives, Latin American Responses, 2010
Chart 4-14: Preferred Bifurcated Stent Alternatives, Asia-Pacific Responses, 2010
Chart 4-15: Preferred Bifurcated Stent Alternatives, Middle Eastern and African Responses, 2010
Chart 4-16: Bioabsorbable Stents and Their Use, U.S. Responses, 2010
Chart 4-17: Bioabsorbable Stents and Their Use, European Responses, 2010
Chart 4-18: Bioabsorbable Stents and Their Use, Latin American Responses, 2010
Chart 4-19: Bioabsorbable Stents and Their Use, Asia-Pacific Responses, 2010
Chart 4-20: Bioabsorbable Stents and Their Use, Middle Eastern and African Responses, 2010
Chart 4-21: Most Important Bioabsorbable Stent Benefit, Global Responses, 2010
Chart 4-22: Most Important Bioabsorbable Stent Drawback, Global Responses, 2010
Chart 4-23: Most Important Drug-Eluting Stent Concern, Global Responses, 2010
Chart 4-24: Most Effective Drug-Eluting Stent Drug for Combating Restenosis, U.S. Responses, 2010
Chart 4-25: Most Effective Drug-Eluting Stent Drug for Combating Restenosis, European Responses, 2010
Chart 4-26: Most Effective Drug-Eluting Stent Drug for Combating Restenosis, Latin American Responses, 2010
Chart 4-27: Most Effective Drug-Eluting Stent Drug for Combating Restenosis, Asia-Pacific Responses, 2010
Chart 4-28: Most Effective Drug-Eluting Stent Drug for Combating Restenosis, Middle Eastern and African Responses, 2010
Chart 4-29: Most Effective Drug-Eluting Stent Drug for Combating Restenosis, U.S. Responses, 2010
Chart 4-30: Most Effective Drug-Eluting Stent Drug for Combating Restenosis, European Responses, 2010
Chart 4-31: Most Effective Drug-Eluting Stent Drug for Combating Restenosis, Latin American Responses, 2010
Chart 4-32: Most Effective Drug-Eluting Stent Drug for Combating Restenosis, Asia-Pacific Responses, 2010
Chart 4-33: Most Effective Drug-Eluting Stent Drug for Combating Restenosis, Middle Eastern and African Responses, 2010
Chart 4-34: Most Important Construction Feature for Stent-Grafts, Global Responses, 2010
Chart 4-35: Most Important Design Feature for Next-Generation Stent-Grafts, Global Responses, 2010
Chart 4-36: The Use of Thoracic Aortic Aneurysm (TAA) Stent-Grafts, Global Responses, 2010
Chart 4-37: Concerns about the Use of TAA Stent-Grafts, Global Responses, 2010
Chart 4-38: Most Promising Vulnerable Plaque Screening Technology, Global Responses, 2010
Chart 4-39: Most Promising Vulnerable Plaque Treatment Technology, Global Responses, 2010
U.S. STENTS, STENT-GRAFTS AND VULNERABLE PLAQUE
Chart 5-1: Total Number of Stents Placed per Month, U.S. Responses, 2010
Chart 5-2: Number of Coronary Stents Placed per Month, U.S. Responses, 2010
Chart 5-3: Number of Peripheral Stents Placed per Month, U.S. Responses, 2010
Chart 5-4: Type of Medical Imaging Used for Endovascular Procedures, U.S. Responses, 2010
Chart 5-5: Bifurcated Stents and Their Use, U.S. Responses,
Chart 5-6: Most Important Benefit When Using Bifurcated Stents, U.S. Responses, 2010
Chart 5-7: Drawbacks to the Use of Bifurcated Stents, U.S. Responses, 2010
Chart 5-8: Preferred Bifurcated Stent Alternatives, U.S. Responses, 2010
Chart 5-9: Preferred Bifurcated Stent Alternatives by Specialty, U.S. Responses, 2010
Chart 5-10: Bioabsorbable Stents and Their Use, U.S. Responses, 2010
Chart 5-11: Most Important Benefit When Using Bioabsorbable Stents, U.S. Responses, 2010
Chart 5-12: Most Important Bioabsorbable Stent Drawback, U.S. Responses, 2010
Chart 5-13: Most Important Drug-Eluting Stent Concern, U.S. Responses, 2010
Chart 5-14: Most Effective Drug-Eluting Stent Drug for Combating Restenosis, U.S. Responses, 2010
Chart 5-15: Most Effective Drug-Eluting Stent Drug for Combating Restenosis by Specialty, U.S. Responses, 2010
Chart 5-16: Preferred Brand of Stent-Graft, U.S. Responses, 2010
Chart 5-17: Most Important Construction Feature for Stent-Grafts, U.S. Responses, 2010
Chart 5-18: Most Important Design Feature for Next-Generation Stent-Grafts, U.S. Responses, 2010
Chart 5-19: Use of TAA Stent-Grafts, U.S. Responses, 2010
Chart 5-20: Concerns about the Use of TAA Stent-Grafts, U.S. Responses, 2010
Chart 5-21: Most Promising Vulnerable Plaque Screening Technology, U.S. Responses, 2010
Chart 5-22: Most Promising Vulnerable Plaque Screening Technology by Specialty, U.S. Responses, 2010
Chart 5-23: Most Promising Vulnerable Plaque Treatment Technology, U.S. Responses, 2010
Chart 5-24: Most Promising Vulnerable Plaque Treatment Technology by Specialty, U.S. Responses, 2010
EUROPEAN STENTS, STENT-GRAFTS AND VULNERABLE PLAQUE
Chart 6-1: Total Number of Stents Placed per Month, European Responses, 2010
Chart 6-2: Number of Coronary Stents Placed per Month, European Responses, 2010
Chart 6-3: Number of Peripheral Stents Placed per Month, European Responses, 2010
Chart 6-4: Type of Medical Imaging Used for Endovascular Procedures, European Responses, 2010
Chart 6-5: Bifurcated Stents and Their Use, European Responses, 2010
Chart 6-6: Most Important Benefit When Using Bifurcated Stents, European Responses, 2010
Chart 6-7: Drawbacks to the Use of Bifurcated Stents, European Responses, 2010
Chart 6-8: Preferred Bifurcated Stent Alternatives, European Responses, 2010
Chart 6-9: Preferred Bifurcated Stent Alternatives by Specialty, European Responses, 2010
Chart 6-10: Bioabsorbable Stents and Their Use, European Responses, 2010
Chart 6-11: Most Important Benefit When Using Bioabsorbable Stents, European Responses, 2010
Chart 6-12: Most Important Bioabsorbable Stent Drawback, European Responses, 2010
Chart 6-13: Most Important Drug-Eluting Stent Concern, European Responses, 2010
Chart 6-14: Most Effective Drug-Eluting Stent Drug for Combating Restenosis, European Responses, 2010
Chart 6-15: Most Effective Drug-Eluting Stent Drug for Combating Restenosis by Specialty, European Responses, 2010
Chart 6-16: Preferred Brand of Stent-Graft, European Responses, 2010
Chart 6-17: Most Important Construction Feature for Stent-Grafts, European Responses, 2010
Chart 6-18: Most Important Design Feature for Next-Generation Stent-Grafts, European Responses, 2010
Chart 6-19: Use of Thoracic Aortic Aneurysm (TAA) Stent-Grafts, European Responses, 2010
Chart 6-20: Concerns about the Use of TAA Stent-Grafts, European Responses, 2010
Chart 6-21: Most Promising Vulnerable Plaque Screening Technology, European Responses, 2010
Chart 6-22: Most Promising Vulnerable Plaque Screening Technology by Specialty, European Responses, 2010
Chart 6-23: Most Promising Vulnerable Plaque Treatment Technology, European Responses, 2010
LATIN AMERICAN STENTS, STENT-GRAFTS AND VULNERABLE PLAQUE
Chart 7-1: Total Number of Stents Placed per Month, Latin American Responses, 2010
Chart 7-2: Number of Coronary Stents Placed per Month, Latin American Responses, 2010
Chart 7-3: Number of Peripheral Stents Placed per Month, Latin American Responses, 2010
Chart 7-4: Type of Medical Imaging Used for Endovascular Procedures, Latin American Responses, 2010
Chart 7-5: Type of Medical Imaging Used for Endovascular Procedures by Country, Latin American Responses, 2010
Chart 7-6: Bifurcated Stents and Their Use, Latin American Responses, 2010
Chart 7-7: Most Important Benefit When Using Bifurcated Stents, Latin American Responses, 2010
Chart 7-8: Drawbacks to the Use of Bifurcated Stents, Latin American Responses, 2010
Chart 7-9: Preferred Bifurcated Stent Alternatives, Latin American Responses, 2010
Chart 7-10: Bioabsorbable Stents and Their Use, Latin American Responses, 2010
Chart 7-11: Most Important Benefit When Using Bioabsorbable Stents, Latin American Responses, 2010
Chart 7-12: Most Important Bioabsorbable Stent Drawback, Latin American Responses, 2010
Chart 7-13: Most Important Drug-Eluting Stent Concern, Latin American Responses, 2010
Chart 7-14: Most Effective Drug-Eluting Stent Drug for Combating Restenosis, Latin American Responses, 2010
Chart 7-15: Preferred Brand of Stent-Graft, Latin American Responses, 2010
Chart 7-16: Most Important Construction Feature for Stent-Grafts, Latin American Responses, 2010
Chart 7-17: Most Important Design Feature for Next-Generation Stent-Grafts, Latin American Responses, 2010
Chart 7-18: Concerns about the Use of TAA Stent-Grafts, Latin American Responses, 2010
Chart 7-19: Most Promising Vulnerable Plaque Screening Technology, Latin American Responses, 2010
Chart 7-20: Most Promising Vulnerable Plaque Treatment Technology, Latin American Responses, 2010
ASIA-PACIFIC STENTS, STENT-GRAFTS AND VULNERABLE PLAQUE
Chart 8-1: Total Number of Stents Placed per Month, Asia-Pacific Responses, 2010
Chart 8-2: Number of Coronary Stents Placed per Month, Asia-Pacific Responses, 2010
Chart 8-3: Number of Peripheral Stents Placed per Month, Asia-Pacific Responses, 2010
Chart 8-4: Type of Medical Imaging Used for Endovascular Procedures, Asia-Pacific Responses, 2010
Chart 8-5: Bifurcated Stents and Their Use, Asia-Pacific Responses, 2010
Chart 8-6: Most Important Benefit When Using Bifurcated Stents, Asia-Pacific Responses, 2010
Chart 8-7: Drawbacks to the Use of Bifurcated Stents, Asia-Pacific Responses, 2010
Chart 8-8: Preferred Bifurcated Stent Alternatives, Asia-Pacific Responses, 2010
Chart 8-9: Bioabsorbable Stents and Their Use, Asia-Pacific Responses, 2010
Chart 8-10: Most Important Benefit When Using Bioabsorbable Stents, Asia-Pacific Responses, 2010
Chart 8-11: Most Important Bioabsorbable Stent Drawback, Asia-Pacific Responses, 2010
Chart 8-12: Most Important Drug-Eluting Stent Concern, Asia-Pacific Responses, 2010
Chart 8-13: Most Effective Drug-Eluting Stent Drug for Combating Restenosis, Asia-Pacific Responses, 2010
Chart 8-14: Preferred Brand of Stent-Graft, Asia-Pacific Responses, 2010
Chart 8-15: Most Important Construction Feature for Stent-Grafts, Asia-Pacific Responses, 2010
Chart 8-16: Most Important Design Feature for Next-Generation Stent-Grafts, Asia-Pacific Responses, 2010
Chart 8-17: Concerns about the Use of TAA Stent-Grafts, Asia-Pacific Responses, 2010
Chart 8-18: Most Promising Vulnerable Plaque Screening Technology, Asia-Pacific Responses, 2010
Chart 8-19: Most Promising Vulnerable Plaque Treatment Technology, Asia-Pacific Responses, 2010
MIDDLE EASTERN AND AFRICAN STENTS, STENT-GRAFTS AND VULNERABLE PLAQUE
Chart 9-1: Total Number of Stents Placed per Month, Middle Eastern and African Responses, 2010
Chart 9-2: Number of Coronary Stents Placed per Month, Middle Eastern and African Responses, 2010
Chart 9-3: Number of Peripheral Stents Placed per Month, Middle Eastern and African Responses, 2010
Chart 9-4: Type of Medical Imaging Used for Endovascular Procedures, Middle Eastern and African Responses, 2010
Chart 9-5: Bifurcated Stents and Their Use, Middle Eastern and African Responses, 2010
Chart 9-6: Most Important Benefit When Using Bifurcated Stents, Middle Eastern and African Responses, 2010
Chart 9-7: Drawbacks to the Use of Bifurcated Stents, Middle Eastern and African Responses, 2010
Chart 9-8: Preferred Bifurcated Stent Alternatives, Middle Eastern and African Responses, 2010
Chart 9-9: Bioabsorbable Stents and Their Use, Middle Eastern and African Responses, 2010
Chart 9-10: Most Important Benefit When Using Bioabsorbable Stents, Middle Eastern and African Responses, 2010
Chart 9-11: Most Important Bioabsorbable Stent Drawback, Middle Eastern and African Responses, 2010
Chart 9-12: Most Important Drug-Eluting Stent Concern, Middle Eastern and African Responses, 2010
Chart 9-13: Most Effective Drug-Eluting Stent Drug for Combating Restenosis, Middle Eastern and African Responses, 2010
Chart 9-14: Preferred Brand of Stent-Graft, Middle Eastern and African Responses, 2010
Chart 9-15: Most Important Construction Feature for Stent-Grafts, Middle Eastern and African Responses, 2010
Chart 9-16: Most Important Design Feature for Next-Generation Stent-Grafts, Middle Eastern and African Responses, 2010
Chart 9-17: Use of Thoracic Aortic Aneurysm (TAA) Stent-Grafts, Middle Eastern and African Responses, 2010
Chart 9-18: Concerns about the Use of TAA Stent-Grafts, Middle Eastern and African Responses, 2010
Chart 9-19: Most Promising Vulnerable Plaque Screening Technology, Middle Eastern and African Responses, 2010
Chart 9-20: Most Promising Vulnerable Plaque Treatment Technology, Middle Eastern and African Responses, 2010
ABBREVIATIONS
APPENDIX
Skip to top


Ask Your Question

Global Physician Survey on Stents, Stent-Grafts and Vulnerable Plaque Treatment 2011
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: